vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Bandwidth Inc. (BAND). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $208.8M, roughly 1.7× Bandwidth Inc.). Bandwidth Inc. runs the higher net margin — 1.9% vs -0.8%, a 2.7% gap on every dollar of revenue. On growth, Bandwidth Inc. posted the faster year-over-year revenue change (20.1% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $-1.0M). Over the past eight quarters, Bandwidth Inc.'s revenue compounded faster (9.7% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Bandwidth Inc. is a communications platform as a service company. It sells software application programming interfaces for voice, text messaging and emergency services, using its own global IP voice network.
ASIX vs BAND — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $208.8M |
| Net Profit | $-2.8M | $4.0M |
| Gross Margin | 7.6% | 37.3% |
| Operating Margin | -0.7% | 60.5% |
| Net Margin | -0.8% | 1.9% |
| Revenue YoY | 9.4% | 20.1% |
| Net Profit YoY | -892.9% | 200.0% |
| EPS (diluted) | $-0.11 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $208.8M | ||
| Q4 25 | $359.9M | $207.7M | ||
| Q3 25 | $374.5M | $191.9M | ||
| Q2 25 | $410.0M | $180.0M | ||
| Q1 25 | $377.8M | $174.2M | ||
| Q4 24 | $329.1M | $210.0M | ||
| Q3 24 | $398.2M | $193.9M | ||
| Q2 24 | $453.5M | $173.6M |
| Q1 26 | — | $4.0M | ||
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-2.6M | $-1.2M | ||
| Q2 25 | $31.4M | $-4.9M | ||
| Q1 25 | $23.3M | $-3.7M | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $413.0K | ||
| Q2 24 | $38.9M | $4.1M |
| Q1 26 | — | 37.3% | ||
| Q4 25 | 7.6% | 37.6% | ||
| Q3 25 | 6.8% | 38.5% | ||
| Q2 25 | 14.3% | 39.8% | ||
| Q1 25 | 14.2% | 41.0% | ||
| Q4 24 | 3.4% | 36.4% | ||
| Q3 24 | 14.4% | 37.7% | ||
| Q2 24 | 17.9% | 37.3% |
| Q1 26 | — | 60.5% | ||
| Q4 25 | -0.7% | -1.9% | ||
| Q3 25 | -0.9% | -1.0% | ||
| Q2 25 | 7.7% | -2.1% | ||
| Q1 25 | 7.7% | -2.7% | ||
| Q4 24 | -3.9% | -1.3% | ||
| Q3 24 | 7.5% | -0.5% | ||
| Q2 24 | 11.5% | -3.5% |
| Q1 26 | — | 1.9% | ||
| Q4 25 | -0.8% | — | ||
| Q3 25 | -0.7% | -0.6% | ||
| Q2 25 | 7.7% | -2.7% | ||
| Q1 25 | 6.2% | -2.1% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | 0.2% | ||
| Q2 24 | 8.6% | 2.3% |
| Q1 26 | — | $-0.08 | ||
| Q4 25 | $-0.11 | $-0.10 | ||
| Q3 25 | $-0.10 | $-0.04 | ||
| Q2 25 | $1.15 | $-0.16 | ||
| Q1 25 | $0.86 | $-0.13 | ||
| Q4 24 | $0.02 | $0.27 | ||
| Q3 24 | $0.82 | $0.01 | ||
| Q2 24 | $1.43 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $47.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $405.7M |
| Total Assets | $1.7B | $984.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $47.3M | ||
| Q4 25 | $19.8M | $111.3M | ||
| Q3 25 | $23.7M | $80.4M | ||
| Q2 25 | $18.4M | $68.1M | ||
| Q1 25 | $8.3M | $41.7M | ||
| Q4 24 | $19.6M | $83.8M | ||
| Q3 24 | $17.3M | $79.9M | ||
| Q2 24 | $12.1M | $76.4M |
| Q1 26 | — | $405.7M | ||
| Q4 25 | $815.2M | $400.0M | ||
| Q3 25 | $818.2M | $392.7M | ||
| Q2 25 | $823.7M | $384.5M | ||
| Q1 25 | $794.4M | $345.4M | ||
| Q4 24 | $774.6M | $312.5M | ||
| Q3 24 | $766.4M | $336.6M | ||
| Q2 24 | $746.6M | $307.4M |
| Q1 26 | — | $984.2M | ||
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.7B | $1.0B | ||
| Q2 25 | $1.6B | $1.0B | ||
| Q1 25 | $1.6B | $964.4M | ||
| Q4 24 | $1.6B | $989.2M | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.5B | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | — |
| Free Cash FlowOCF − Capex | $36.1M | $-1.0M |
| FCF MarginFCF / Revenue | 10.0% | -0.5% |
| Capex IntensityCapex / Revenue | 7.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $38.6M | ||
| Q3 25 | $26.6M | $22.2M | ||
| Q2 25 | $21.1M | $31.7M | ||
| Q1 25 | $11.4M | $-3.1M | ||
| Q4 24 | $64.2M | $36.5M | ||
| Q3 24 | $57.3M | $20.5M | ||
| Q2 24 | $50.2M | $24.4M |
| Q1 26 | — | $-1.0M | ||
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — |
| Q1 26 | — | -0.5% | ||
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | 49.55× | ||
| Q2 24 | 1.29× | 6.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
BAND
Segment breakdown not available.
